BioSpace News Archive

Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended June 30, 2023, and recent business highlights.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2023 and provided a business update.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, announced its second quarter 2023 financial results and provided recent operating highlights for the clinical programs in ALS and MS.

VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today provided a business update and reported financial results for the second quarter of 2023.

Adverum Biotechnologies, Inc. today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference on Wednesday, August 16, 2023.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported additional positive results from its proof-of-concept Phase 2 open-label clinical trial (NCT05448755) of ELX-02 for the treatment of Alport syndrome after eight weeks of treatment.

IceCure Medical Ltd. reported financial results as of and for the six months ended June 30, 2023, as well as operational and recent corporate developments.

NeuroBo Pharmaceuticals, Inc. today announced the appointment of current Board member, Hyung Heon (“H.H.”) Kim, as the Company’s Chief Executive Officer and President, effective immediately.

Enveric Biosciences, Inc. today provided a corporate update and reported financial results for the second quarter of 2023 ended June 30, 2023.